Cholangiocarcinoma and hepatocellular carcinoma are primary liver cancers, both representing a growing challenge due to their increasing morbidity and mortality. A “metronomic chemotherapy”, consisting of the repeated administration of low and/or continuous doses of anti-neoplastic drugs, represents an alternative approach to the standard chemotherapy [1]. Numerous natural substances exhibited in vitro chemosensitizing features: in particular, the natural sesquiterpene β-caryophyllene (CRY) has been proved to increase the cytotoxicity of doxorubicin (DOXO) in leukemic cells [2]. Hence, our aim has been to evaluate the ability of CRY to enhance the efficacy of low-dose DOXO in human liver cancer cells, by applying a metronomic protocol. To this end, human liver HepG2 and CCA cells have been used as models of hepatocellular carcinoma and cholangiocarcinoma. The metronomic protocol was based on a 2h low-time exposition to the test substances, followed by 72h incubation for restoring. This scheduling has been applied 3 times and cytotoxicity was measured by MTT assay. Both the substances alone (CRY 1-100 μg/ml; DOXO 1-500 μg/ml) and the combination of DOXO with a nontoxic concentration of CRY were assessed. We found that the repeated treatments with low concentrations produced a significant potentiation (about 30 %) of DOXO cytotoxicity in HepG2. The combination with CRY increased the DOXO activity, reaching a 70 % inhibition of cell viability at 50 μg/ml after 2 repeated treatments. Similar effects were found in CCA, although repeated treatments induced no additional potentiation. These results highlight a possible role of CRY as a chemosensitizing agent for DOXO-based chemotherapy of liver cancer.
β-caryophyllene and low-doses of doxorubicin against liver cancer cells: a “metronomic chemotherapy” / Mancinelli, Romina; DI SOTTO, Antonella; Abete, Lorena; Vecchiato, Martina; DI GIACOMO, Silvia; Vitalone, Annabella; Mazzanti, Gabriela; Mammola, CATERINA LOREDANA. - In: ITALIAN JOURNAL OF ANATOMY AND EMBRYOLOGY. - ISSN 2038-5129. - STAMPA. - 122:1 (supplement)(2017), pp. 130-130. (Intervento presentato al convegno 71° congresso della Società Italiana di Anatomia ed Istologia tenutosi a Taormina nel 20-22 settembre 2017) [10.13128/IJAE-21522].
β-caryophyllene and low-doses of doxorubicin against liver cancer cells: a “metronomic chemotherapy”
Romina Mancinelli;Antonella Di Sotto;Lorena Abete;Martina Vecchiato;Silvia Di Giacomo;Annabella Vitalone;Gabriela Mazzanti;Caterina Loredana Mammola
2017
Abstract
Cholangiocarcinoma and hepatocellular carcinoma are primary liver cancers, both representing a growing challenge due to their increasing morbidity and mortality. A “metronomic chemotherapy”, consisting of the repeated administration of low and/or continuous doses of anti-neoplastic drugs, represents an alternative approach to the standard chemotherapy [1]. Numerous natural substances exhibited in vitro chemosensitizing features: in particular, the natural sesquiterpene β-caryophyllene (CRY) has been proved to increase the cytotoxicity of doxorubicin (DOXO) in leukemic cells [2]. Hence, our aim has been to evaluate the ability of CRY to enhance the efficacy of low-dose DOXO in human liver cancer cells, by applying a metronomic protocol. To this end, human liver HepG2 and CCA cells have been used as models of hepatocellular carcinoma and cholangiocarcinoma. The metronomic protocol was based on a 2h low-time exposition to the test substances, followed by 72h incubation for restoring. This scheduling has been applied 3 times and cytotoxicity was measured by MTT assay. Both the substances alone (CRY 1-100 μg/ml; DOXO 1-500 μg/ml) and the combination of DOXO with a nontoxic concentration of CRY were assessed. We found that the repeated treatments with low concentrations produced a significant potentiation (about 30 %) of DOXO cytotoxicity in HepG2. The combination with CRY increased the DOXO activity, reaching a 70 % inhibition of cell viability at 50 μg/ml after 2 repeated treatments. Similar effects were found in CCA, although repeated treatments induced no additional potentiation. These results highlight a possible role of CRY as a chemosensitizing agent for DOXO-based chemotherapy of liver cancer.File | Dimensione | Formato | |
---|---|---|---|
Mancinelli_Caryophyllene_ 2017.pdf
accesso aperto
Note: Abstract
Tipologia:
Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza:
Creative commons
Dimensione
175.72 kB
Formato
Adobe PDF
|
175.72 kB | Adobe PDF | |
Mancinelli_Frontespizio_Caryophyllene_ 2017.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Creative commons
Dimensione
153.49 kB
Formato
Unknown
|
153.49 kB | Unknown | |
Mancinelli_Quarta_Caryophyllene_ 2017.pdf
accesso aperto
Tipologia:
Altro materiale allegato
Licenza:
Creative commons
Dimensione
46.5 kB
Formato
Unknown
|
46.5 kB | Unknown |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.